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Selective inhibition of BET bromodomain epigenetic
signalling interferes with the bone-associated
tumour vicious cycle
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The vicious cycle established between bone-associated tumours and bone resorption is the
central problem with therapeutic strategies against primary bone tumours and bone
metastasis. Here we report data to support inhibition of BET bromodomain proteins as a
promising therapeutic strategy that target simultaneously the three partners of the vicious
cycle. Treatment with JQ1, a BET bromodomain inhibitor, reduces cell viability of osteo-
sarcoma cells and inhibits osteoblastic differentiation both in vitro and in vivo. These effects
are associated with transcriptional silencing of MYC and RUNX2, resulting from
the depletion of BRD4 from their respective loci. Moreover, JQ1 also inhibits osteoclast
differentiation by interfering with BRD4-dependent RANKL activation of NFATC1 transcription.
Collectively, our data indicate that JQ1 is a potent inhibitor of osteoblast and osteoclast
differentiation as well as bone tumour development.
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B
one malignancies can be divided into two classes, primary
and secondary bone tumours. Secondary bone tumours
arise from disseminated tumour cells that originate from
distant primary sites, most commonly from breast, prostate and
lung cancers, which subsequently give rise to metastatic
development in the bone1. Malignant primary bone tumours
are rare pathologies, with osteosarcoma being the most frequent
type in children and young adults and have a poor prognosis
owing to its propensity to metastasize. Osteosarcoma is deﬁned as
a malignant tumour of mesenchymal cells and its diagnosis is
based on histopathological features characterized by the direct
formation of abnormal osteoid and/or woven bone2. Current
therapeutic regimens for osteosarcoma include neoadjuvant and
adjuvant chemotherapy combined with tumour resection3. While
survival rate can reach 70% at 5 years in the best series, survival
rate is signiﬁcantly reduced to only 30% when pulmonary
metastases are detected at the time of diagnosis. Thus, the overall
clinical outcome remains poor despite treatment advances, which
underscores the need to identify novel therapeutic strategies for
osteosarcoma.
The vicious cycle established between osteoclasts (OCs), bone
stromal cells/osteoblasts (OBs) and cancer cells is the driving
force of osteolytic lesions during progression of primary bone
tumours4–6. Histological analyses of osteolytic primary and
secondary bone tumours reveal that the bone destruction is
mediated by OCs rather than the tumour cells themselves. The
tumour cells modify the bone microenvironment and promote
the recruitment of OC progenitors by secreting osteoclastic-
activating factors such as interleukin (IL)6, tumour necrosis
factor-a, IL1 and parathyroid hormone-related protein. The OCs,
in turn, resorb bone tissue and release from the bone matrix
growth factors that stimulate the proliferation of tumour cells6.
A key pathway implicated in OC activation is the receptor
activator of nuclear factor kappaB (NFkB) and its ligand
(RANK/RANKL), which induces the expression of nuclear
factor of activated T cells, cytoplasmic 1 (NFATC1), a master
transcription factor of OC differentiation and one of its
downstream effectors like matrix metallopeptidase 9 (MMP9).
Given that the interplay between tumour growth and bone
resorption is the basis of the vicious cycle of osteosarcoma,
a potential therapeutic strategy is to disrupt this cycle by
targeting OC and OB differentiation as well as tumour cell
proliferation.
Several genes have been identiﬁed as drivers of osteosarcoma
development. c-MYC (hereafter referred as MYC) is one of the
most highly ampliﬁed oncogenes in cancer. It encodes an
evolutionarily conserved basic helix-loop-helix leucine zipper
transcription factor that is commonly deregulated in numerous
types of human malignancies. Owing to a large number of direct
transcriptional targets and the resulting activation of many
transcriptional and signalling networks, ampliﬁcation of MYC
results in pleiotropic effects on cancer cell survival, proliferation,
metastasis and angiogenesis7. Genomic ampliﬁcation at 8q24 and
overexpression of MYC has been observed in osteosarcoma8–10.
Moreover,MYC overexpression in a Ink4/Arf( / ) context was
not only sufﬁcient to transform bone marrow stromal cells but
also led to osteosarcoma development11. In addition, RUNX2, a
key transcription factor in OB differentiation, appears to be a
potential oncogenic driver in osteosarcoma, depending on its
expression level and cellular context12–15. Indeed, short
interfering RNA (siRNA) knockdown of RUNX2 in U2OS
osteosarcoma cells was shown to inhibit cell growth, while
overexpression of RUNX2 in T-cell lymphoma synergized with
MYC to promote survival and proliferation of cancer cells13,16.
Thus, inhibition of MYC and RUNX2 transcriptional network
may be of clinical relevance in osteosarcoma.
Histone modiﬁcations are of critical importance for the
maintenance of the transcription programme of both normal
and tumour cells. Post-translational covalent modiﬁcations of the
histone amino-terminal tail inﬂuence chromatin structure and
the accessibility of DNA to transcriptional machinery. The
bromodomain and extra-terminal domain (BET) protein family
(BRD2, BRD3, BRD4 and BRDT) is an important class of
‘epigenetic reader proteins’, which function to recognize the
N-acetylation of lysine residues on histone tails17. Bromodomain-
containing proteins act as a scaffold for molecular complexes at
recognized histones’ sites to regulate chromatin accessibility to
transcription factors and RNA polymerase18. Very recently,
BRD4 has been identiﬁed as a potent therapeutic target in acute
myeloid leukaemia19,20. Moreover, the BET bromodomain
proteins have been shown to regulate the expression of MYC in
different tumour types19–25. Several studies have tested the
pharmacologic inhibition of bromodomains using JQ1, a
thienotriazolo-1,4-diazapine that binds selectively to the acetyl-
lysine-binding pocket of the BET bromodomain proteins,
inhibiting only BRD2, BRD3, BRD4 and BRDT among the 47
bromodomain proteins with a prevalent afﬁnity for BRD4
(ref. 26). Pharmacologic inhibition of bromodomains leads to
selective alterations in gene expression most probably owing to
the disruption of strong enhancer-mediated transcription at
oncogenic loci, such as those bound by MYC. Indeed, gene set
enrichment analysis indicates that one of the most deregulated
network is the MYC transcriptome22. Furthermore, JQ1
treatment resulted in a reduction of MYC expression as well as
induced cell death in multiple myeloma, leukaemia and
lymphoma both in vitro and in vivo20,21.
In this study, we show that BET bromodomain signalling plays
a role in osteosarcoma and that inhibition of this epigenetic
recognition pathway suppresses osteosarcoma tumour growth
both in vitro and in vivo. We also identify RUNX2 as a new direct
transcriptional target of BRD4, linked to the bone-associated
tumour context as inhibition of RUNX2 reduced both osteoblastic
differentiation and primary bone tumour development. In
addition, we show that the unique and selective BET bromodo-
main inhibitor JQ1 potently represses not only MYC gene
expression but also RUNX2 gene expression as well as their
transcriptional network in osteosarcoma cell lines and in vivo
tumour models. The JQ1-mediated transcriptional silencing of
MYC and RUNX2 corresponds with the release of BRD4 from
their respective loci, which further supports the direct transcrip-
tional activation of these genes by BRD4. Finally, we uncover a
BRD4-dependent RANKL activation pathway in osteoclasto-
genesis, which is also inhibited by JQ1 treatment. Taken together,
our ﬁndings indicate that targeting the BET bromodomain
signalling pathway in primary bone cancer can effectively disrupt
the vicious cycle through transcriptional repression of oncogenic
drivers in osteosarcoma as well as through the inhibition of
OB and OC differentiation. Importantly, our work provides a
strong clinical rationale for the use of BET bromodomain
inhibitors, speciﬁcally JQ1, as a therapeutic approach for
osteosarcoma.
Results
BET bromodomain proteins and MYC overexpression in
patients. To assess the therapeutic potential of targeting BET
bromodomain signalling in osteosarcoma, we ﬁrst evaluated the
messenger RNA expression level in human osteosarcoma patient
samples of BRD2, BRD3, BRD4 and BRDT as well as MYC, since
it has been associated to the BRD4 inhibition effects17,18.
Compared with normal mesenchymal stem cells (MSCs), 9 out
of 14 patients overexpressed both BRD4 and MYC, 11 out of 14
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overexpressed BRD2 and MYC and 7 out of 14 overexpressed
BRD3 and MYC (Fig. 1a and Supplementary Fig. 1). None of the
patients expressed BRDT, which is a tissue-speciﬁc protein. This
ﬁnding suggests that the majority of osteosarcoma patients
express the required molecular targets for an inhibition of BET
bromodomains epigenetic signalling strategy, which is the
minimal rational to make them candidates to this therapy.
Moreover, we observed a strong correlation (Po0.001) between
the expression level of BRD4 with MYC, using the Pearson
product-moment correlation coefﬁcient (R2; Fig. 1b). As the size
of our patient cohort was limited, we validated this correlation in
a lager cohort of 27 osteosarcoma patients’ biopsy samples
obtained by Dr Yamada T from the National Cancer Center of
Tokyo (GEO Series GSE14827)27. The expression array study
conﬁrmed the strong correlation between BRD4 and MYC
expression level (Supplementary Fig. 2).
No correlation has been observed between MYC and BRD2 or
BRD3 using either our patient tumour samples or the larger
Yamada lab cohort. Unfortunately, the sizes of our patient cohort
or even the complete Yamada’s patient cohort are not big enough
to correlate the clinical outcome of the patient with BRD4 or
MYC expression or with age, sex, tumour location, histological
origin or response to chemotherapy (Fig. 1c and Supplementary
Fig. 2). We then evaluated the BRD2, BRD3, BRD4 and MYC
expression level in various patient-derived osteosarcoma cell lines
and murine osteosarcoma cell lines. We observed an interesting
variability, comparable to our patient cohort, which prompted a
more detailed study of BET bromodomain signalling in
osteosarcoma (Fig. 1d and Supplementary Figs 1 and 3).
Inhibition of BET bromodomain proteins in vitro. To evaluate
the therapeutic potential of BET bromodomain inhibition in
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Figure 1 | Brd4 and MYC messenger RNA levels are overexpressed in osteosarcoma patients. (a) Expression of BRD4 and MYC mRNA levels were
evaluated by qRT–PCR in human osteosarcoma biopsies compared with normal cells. (b) Correlation between BRD4 and MYC expression in human
osteosarcoma specimens, assessed by qRT–PCR and tested by the Pearson product-moment correlation test. (c) Clinical features of osteosarcoma patients.
(d) Expression of BRD4 andMYCmRNA levels in human osteosarcoma cell lines, assessed by qRT–PCR. Error bars show s.e.m. for n¼ 3 measurement from
representative experiments.
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osteosarcoma, we used the pharmacological inhibitor JQ1,
a thienotriazolo-1,4-diazapine that binds selectively to the
acetyl-lysine-binding pocket of the BET bromodomain protein
(Fig. 2a)26. We ﬁrst treated a panel of nine genetically deﬁned
human osteosarcoma cell lines (Fig. 2b) with the BET inhibitor
JQ1 to assess its effect on cell viability. A dose-dependent
inhibition of cell viability was observed in all cell lines studied.
Comparison of the GI50 of each tumour cell line revealed no
signiﬁcant difference in cell viability sensitivity for MNNG/HOS,
KHOS, U2OS and MG63 cell lines as they exhibited a GI50
between 0.268 and 1.081 mM. In contrast, the others cell lines
tested were about 10 times more resistant compared with the ﬁrst
ones, among them, SaOS2 cells with a GI50 of 6.457 mM (Fig. 2b).
Then we performed a colony formation assay in the presence or
absence of JQ1, which revealed signiﬁcant differences between the
cell lines in terms of their capacity to recover following 2 days
of BET inhibitor treatment (1 mM). Indeed, while U2OS and
MNNG/HOS exhibited signiﬁcant reduction in colony formation,
MG63 and SaOS2, respectively, exhibited moderate sensitivity or
no sensitivity at all to JQ1 treatment (Fig. 2c,d). These differences
were further conﬁrmed by cell cycle analysis. The proportion
of cells in subG1 (representing dead cells as determined by
propidium iodide staining) was strongly induced by JQ1
treatment in U2OS and MNNG/HOS, but was only modestly
increased in MG63 and unchanged in SaOS2 (Fig. 2e). Finally,
apoptosis was evaluated in osteosarcoma cells by assessing
the level of cleaved poly (ADP-ribose) polymerase after JQ1
treatment. Consistent with the results of the colony formation
assays and cell cycle analysis, the same sensitivity proﬁle was
observed in the two cell lines with the lowest level of both BRD4
and MYC, namely, MNNG/HOS and U2OS were the most
sensitive to apoptosis induction as revealed by the level of cleaved
poly (ADP-ribose) polymerase, whereas two cell lines with a high
level of BRD4 and MYC, namely, MG63 and SaOS2 were more
resistant to the apoptotic effect of JQ1 (Fig. 2f). In addition, the
induced apoptosis was conﬁrmed in MNNG/HOS to be caspase-3
dependent (Supplementary Fig. 4A). These results conﬁrmed
our hypothesis that sensitivity of osteosarcoma tumours to
BET bromodomains signalling inhibition is dependent on the
expression level of BRD4 and MYC. We conﬁrmed this
hypothesis by the study of JQ1-resistant cell lines. We
established MNNG/HOS-resistant cells by long-term exposure
to increasing concentrations of JQ1. Once a signiﬁcant difference
in term of GI50 could be observed, we performed quantitative
reverse transcription (qRT)–PCR expression analysis for the BET
bromodomains and MYC. As predicted by our hypothesis, we
observed an overexpression of MYC and BRD4 in the resistant
cell line, we also observed an overexpression of BRD2 but not
BRD3, suggesting a possible implication of several members of the
BET bromodomain family in the mediation of JQ1 effects
(Supplementary Fig. 4B). The sensitivity of murine osteosarcoma
was also conﬁrmed by the decrease in MYC expression, cell
viability and colony formation in MOS-J, POS-1 and K7M2 cell
lines (Supplementary Fig. 4C,D).
Cell line
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MYC-dependent growth inhibitory effect of BET inhibition.
Since downregulation of MYC expression has been previously
described as a consequence of BRD4 inhibition19, we accordingly
examined the expression level of MYC after JQ1 treatment. In all
the osteosarcoma cell lines tested, JQ1 treatment decreased MYC
expression in a dose- and time-dependent manner (Fig. 3a,
Supplementary Fig. 5A,B). We observed the same results in
murine cell lines (Supplementary Fig. 6). Indeed, after only
30min of 0.5 mM JQ1, MYC expression was decreased by 30% in
all cell lines studied, and 1 h of 0.1 mM JQ1 was sufﬁcient to
observe a signiﬁcant effect (Fig. 3a). To conﬁrm the functional
impact of MYC transcriptional inhibition by JQ1, we assessed its
effect on the expression of the MYC target gene mir-17–92
(Fig. 3b). After 24 h in the presence of 0.5 mM of JQ1, all seven
microRNAs in the mir-17–92 cluster were signiﬁcantly
downregulated (Fig. 3c), Furthermore, p21, a direct target
known to be repressed by the mir-17–92 cluster, was highly
upregulated by 12-fold (Fig. 3d and Supplementary Fig. 7A).
Interestingly, the rapid transcriptional effect of the BET inhibitor
on MYC gene expression suggests the possibility that BET
proteins may exert direct activation of the MYC locus. To
determine whether BET proteins bind directly to the MYC locus,
we performed chromatin immunoprecipitation (ChIP) studies by
using an antibody targeting BRD4 in MNNG/HOS cells. We
detected speciﬁc enrichment of BRD4 within the MYC promoter
region at several locations including both upstream and
downstream sites relative to the transcriptional start site
(Fig. 3e). Furthermore, treatment of these cells with JQ1
induced the release of BRD4 from the promoter and binding
sites (Fig. 3e, bottom). The presence of DNAse hypersensitive
sites and increased enrichment for histone 3 lysine 27 acetylation
(H3K27ac) at the MYC promoter region indicates active
transcription, perhaps associated with ‘super-enhancer region’
as recently described28,29. The speciﬁcity of the BRD4 antibody
used in this study was assessed in a gene desert region that
displayed no BRD4 enrichment. As mentioned for the resistance
experiment, it looks like BRD2 (but not BRD3) might also be
involved in the JQ1 effects on osteosarcoma. To validate our
hypothesis, we performed the same ChIP at the MYC promoter
region with a BRD2 antibody. While we observed an enrichment
of BRD2 for the same regulatory areas as BRD4 on the MYC
promoter region, no release of BRD2 was observed in the
presence of JQ1. We even observed an opposite effect with a
strong enrichment of BRD2 after JQ1 treatment. This effect is
possibly due to the higher afﬁnity of JQ1 for BRD4, interfering in
the competition between BRD2 and BRD4 for the same binding
sites. This effect did not lead to moreMYC transcription, which is
in agreement with the fact that neither BRD3 nor BRD2 were
correlated with MYC expression in our patient cohort and BRD2
does not seem to be involved in JQ1 effects (Supplementary
Fig. 7B). These ﬁndings demonstrate that BRD4 is present on the
MYC promoter region and that JQ1 is able to deplete BRD4
from the promoter, thus inhibiting MYC transcription in an
osteosarcoma cell line. Next, the growth-promoting activity of
MYC was validated in our model using siRNA (Fig. 3f). To
evaluate whether suppression of MYC mediates the growth
inhibitory effect of BRD4 inhibition by JQ1, we performed a
recovery assay by transfecting MYC or empty vector control
into MNNG/HOS cells (Fig. 3g), followed by treatment with
JQ1. Overexpression of MYC decreased signiﬁcantly the anti-
proliferative effect of JQ1 in osteosarcoma cells. Interestingly, it
did not however inhibit fully the anti-proliferative effect of JQ1.
BET protein inhibition depletes BRD4 from the RUNX2
promoter. As MYC downregulation did not account for all the
anti-proliferative effect of JQ1, we then focused our attention
on RUNX2, a master transcription factor in osteosarcoma and
OB. The expression level of RUNX2 was next evaluated in
osteosarcoma patient samples compared with normal MSCs.
We found that all the patient samples overexpressed RUNX2
(Fig. 4a). Moreover, we observed a strong correlation (Po0.0001)
between the expression levels of BRD4 and RUNX2 using the
Pearson product-moment correlation coefﬁcient (R2; Fig. 4b). We
validated this correlation in a lager cohort of 27 osteosarcoma
patient biopsy samples obtained by Dr Yamada T from the
National Cancer Center of Tokyo (GEO Series GSE14827)27. The
expression array study conﬁrmed the strong correlation between
the expression levels of BRD4 and RUNX2 (Supplementary
Fig. 2).
No correlation has been observed between RUNX2 and BRD2
or BRD3 using either our patient tumour samples or the larger
Yamada’s lab cohort. Next, we evaluated the expression level of
RUNX2 in different osteosarcoma cell lines and murine
osteosarcoma cell lines. We observed an interesting variability,
comparable to that observed within our patient cohort, which
prompted us to study in greater detail the consequences of RUNX2
sensitivity to BET inhibition (Fig. 4c and Supplementary Fig. 3).
Interestingly, the two cell lines that express the highest level of
RUNX2 (MNNG/HOS and U2OS) also express the lowest level of
MYC, suggesting that different oncogenic processes may be
driving these tumour cell lines (Figs 1d and 4c). We next
investigated the expression level of RUNX2 after JQ1 treatment. In
all the examined osteosarcoma cell lines, JQ1 treatment decreased
RUNX2 expression in a time- and dose-dependent manner
(Fig. 4d,e and Supplementary Fig. 8A,B). Similar to MYC, the
growth-promoting activity of RUNX2 in osteosarcoma was
validated in our cell model by siRNA knockdown and colony
formation assay (Fig. 4f). Interestingly, we observed also the
relatively fast transcriptional effects of BET inhibition on RUNX2
gene expression. This ﬁnding suggests that BET proteins might
exert direct effects on the RUNX2 locus. To determine whether
BET proteins bind directly to the RUNX2 locus, we performed
ChIP studies by using an antibody against BRD4 in MNNG/HOS
cells. While no enrichment of BRD4 within the RUNX2 promoter
was detected, speciﬁc binding at the major H3K27 acetylated rich
sites was observed (Fig. 4g). Treatment with JQ1 induced the
release of BRD4 from these sites (Fig. 4g). The presence of DNAse
clusters and the higher level of H3K27 acetylation in the identiﬁed
binding sites indicate transcriptional activity and suggest the
presence of a putative ‘super-enhancer region’28,29. The speciﬁcity
of the BRD4 antibody used in this study was also assessed in a
gene desert region that displayed no BRD4 enrichment. For the
same reasons as the MYC promoter, we performed a BRD2 ChIP
for the RUNX2 locus. While we observed an enrichment of BRD2
for the same regulatory areas as BRD4 on the RUNX2 promoter
region, no release of BRD2 could be observed in the presence of
JQ1. We observed an opposite effect with a strong enrichment of
BRD2 after JQ1 treatment (Supplementary Fig. 8C). To validate
that the speciﬁcity of JQ1 effects on RUNX2 gene expression was
mediated through the inhibition of BRD4-binding activity, we also
assessed BRD4 enrichment at the IL7R locus following JQ1
treatment. IL7R is a recently described target of JQ1, BRD4 being
removed from its promoter after treatment22. In our model,
absolutely no BRD4 binding was detected at the IL7R promoter
area with or without JQ1 treatment, conﬁrming context-speciﬁc
regulation of gene expression (Supplementary Fig. 8D).
JQ1 delays osteosarcoma development and prolongs survival.
To investigate the in vivo therapeutic potential of BET inhibition
in osteosarcoma, we used two models, a human xenograft model
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(using the MNNG/HOS cell line) and a syngeneic model (using
the POS-1 cell line), both of which are known to recapitulate the
features of the human disease. The POS-1 tumour cells were
implanted in C3H mice while MNNG/HOS cells were injected in
athymic mice at day 1 with 2 million cells in paratibial, and mice
were then injected with JQ1 (50mg kg 1 intraperitoneally (IP))
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or vehicle twice a day for the indicated time. JQ1 treatment
had a dramatic anti-tumoral effect, signiﬁcantly reducing the
average tumour volume in both mouse models. (Fig. 5a,e).
Furthermore, the individual tumour volumes of treated mice
compared with control group demonstrated a consistent effect of
the treatment across the groups (Fig. 5b,f). Importantly, not a
single treated mouse had a tumour progression over 1,000mm3 at
day 20 and day 10 for the human and the mouse model,
respectively, while all the untreated mice had tumours that
exceeded that volume (Fig. 5c,g). In both models, the reduction in
tumour volume obtained at the end of the experiment with JQ1
treatment was B60%. The Kaplan–Meier analysis revealed that
JQ1 treatment signiﬁcantly prolonged survival of tumour-bearing
mice. Incredibly, 100% of mice bearing MNNG/HOS tumour cells
and 40% of mice bearing POS-1 cells were still alive with JQ1
treatment at the time when untreated mice were killed as their
tumour volume reached institutional limits (Fig. 5d,h).
Immunohistochemical staining for the proliferative marker Ki67
in tumour samples from mice showed that JQ1 treatment
decreased cell proliferation as compared with the untreated
cohort (Fig. 5i). Expression analysis for MYC and RUNX2 was
also performed on these mice tumour samples. We observed a
signiﬁcant and reproducible repression of MYC and RUNX2
expression with JQ1 treatment, consistent with our in vitro results
(Fig. 5j). Finally, as a functional validation for JQ1-mediated
transcriptional repression of MYC in the mice tumour samples,
we evaluated p21 expression (Fig. 5j). As expected, p21 expression
was highly increased in the mice cohort treated with JQ1. Taken
together, these data suggest that the potent in vivo anti-tumoral
activity of JQ1 in osteosarcoma is probably mediated through
its direct effects on the RUNX2 and MYC/p21 transcriptional
network.
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JQ1 prevents osteosarcoma tumour-associated bone deficiencies.
We next examined the effects of JQ1 on the bone micro-
architecture of tumour-bearing tibia from mice injected with
MNNG/HOS cells using microcomputed tomography (microCT;
Fig. 6a) followed by three-dimensional reconstruction (Fig. 6b).
Surprisingly, JQ1 treatment preserved the bone microarchitecture
as there was a marked reduction in tumour-associated osteolysis,
a common feature of tumour-bearing bone (Fig. 6a,b). An
extensive analysis of multiple bone morphometric parameters
revealed a strong and signiﬁcant amelioration of tumour-
associated bone quality in the JQ1-treated group. Indeed, JQ1
treatment prevented destruction of the trabecular bone
and improved the trabecular bone volume (BV/TV) from 3 to
13% (Fig. 6c), the trabecular number (per mm) from 0.5 to 1.6
(Fig. 6d), the trabecular thickness (mm) from 0.06 to 0.08
(Fig. 6e) and decreased the trabecular separation (mm) from 0.57
to 0.41 (Fig. 6f). One characteristic of osteosarcoma tumours is
the formation of ectopic bone. Our analysis using microCT
showed a strong decrease of this ectopic bone formation in the
presence of JQ1 on the tumour-bearing tibia, with an average of
only 0.13mm3 against 1.73mm3 in the vehicle group (Fig. 6g,h).
Histological analysis of the tumour-bearing bone with tartrate-
resistant acid phosphatase (TRAP) and Osterix staining revealed
that JQ1 treatment strikingly decreased the number of OCs as
well as the number of OBs (Fig. 6i,j). The same bone morpho-
metric analysis was also conducted on tumour-bearing tibia
from the syngeneic mouse model and similar results in bone
quality improvement were observed in the JQ1-treated cohort
(Supplementary Fig. 9).
BET inhibition interferes with the OC and OB differentiation.
Given the surprisingly strong effects of BET bromodomain
HOS xenograft model
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Figure 5 | JQ1 significantly delays tumour growth in MNNG/HOS xenograft and POS-1 syngeneic models and prolongs cancer-specific survival.
Mice were IP injected with 50mg kg 1 JQ1 or vehicle (10% HP-b-CD) twice a day for the indicated time when tumour volume reached 100mm3.
The mean (a, human MNNG/HOS xenograft model and e, mouse POS-1 syngeneic model) or the individual (b,f) tumour volume of mice treated was
compared with control group ±s.e.m. (respectively, n¼ 8 or n¼6). (c,g) The tumour progression was estimated as the relative tumour volumes (RTV)
calculated from the formula: RTV¼ (V20V1) where V20 is the mean tumour volume at day 20 and V1 is the mean tumour volume at day 1 after
starting treatment. (d,h) In Kaplan–Meier curves, cancer-speciﬁc survival were compared between mice treated with JQ1 and control. (i) Tumours
were collected after 35 days (MNNG/HOS xenograft model) or 23 days (POS-1 model) and Ki67 was evaluated by immunohistochemical analysis
(original magniﬁcation,  200; scale bar, 200mm). (j) MYC, p21 and RUNX2 were evaluated in tumour tissues, after RNA extraction, by qRT–PCR.
Error bars show s.e.m. for n¼ 3 measurement from representative experiments.
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proteins inhibition on the bone-microarchitecture, tumour-
associated osteolysis and OC as well as OB number in the tumour
bearing bone, we further evaluated the possible effect of JQ1 on
OC and OB differentiation. First, puriﬁed human CD14þ
monocytes were cultured in the presence of human macrophage
colony stimulating factor and hRANKL to induce osteoclastic
differentiation as well as in the presence or absence of JQ1.
Subsequently, TRAP coloration was performed and the number
of multinucleated cells was assessed (Fig. 7a). BET bromodomain
protein inhibition by JQ1 treatment indeed blocked OC differ-
entiation by more than 80% (Fig. 7b). This block in OC differ-
entiation by JQ1 appears to be independent of its effect on cell
proliferation and survival as it had virtually no effect on the cell
viability of OC precursors. (Supplementary Fig. 10). To begin to
identify the underlying mechanism of JQ1-mediated inhibition of
OC differentiation, we ﬁrst tested the activity of NFkB using a
luciferase-based reporter construct containing its consensus
binding site. Cells expressing RANK were transfected with the
NFkB promoter construct and were then treated with RANKL in
the presence or absence of JQ1. Our results show that treatment
with JQ1 suppressed by more than 50% RANKL-stimulated
NFkB transcriptional activity (Fig. 7c). We then conﬁrmed the
suppressive effect of JQ1 on NFkB activity by examining the
expression of NFkB target genes that are known to be associated
with the differentiation process of OC. JQ1 not only decreased the
expression of NFkB target genes NFATC1 and MMP9 but also
completely abrogated the expression of calcitonin receptor,
a marker of OC differentiation in OC precursors cultured with
RANKL (Fig. 7d–f). Consistent with these ﬁndings, ChIP analysis
conﬁrmed the presence of BRD4 at several NFkB-binding sites on
the NFATC1 and MMP9 promoters. Moreover, we demonstrated
enrichment of BRD4 only when NFkB was activated by RANKL
and that JQ1 was able to deplete BRD4 from these promoters in
RANKL-stimulated OC precursors. As suggested above, BRD2
might be implicated in the JQ1 effects; this hypothesis is even
more relevant in the case of NFkB-dependent promoter like
NFATC1 and MMP9 because signiﬁcant published evidence
shows that BRD2 has a non-redundant, BRD4-independent role
in proliferation and inﬂammation regulating NFkB target genes,
for instance IL-6 and tumour necrosis factor-a transcription30.
We performed a BRD2 ChIP looking at several NFkB-binding
sites on the NFATC1 and MMP9 promoters. While we
demonstrated a RANKL-dependent enrichment of BRD2 on the
NFkB-binding sites, no signiﬁcant depletion of BRD2 in presence
of JQ1 could be observed (Supplementary Fig. 11). Altogether,
these data indicate that JQ1 likely inhibits pro-osteoclastic
differentiation through interference with BRD4-dependent
RANKL activation of NFATC1 and MMP9 transcription
(Fig. 7g and Supplementary Fig. 12). Next, we interrogated the
effect of JQ1 on OB differentiation using human MSCs cultured
in OB differentiation medium as well as in the presence or
absence of JQ1. After 21 days, we assessed OB differentiation by
evaluating the extent of mineralization staining with Alizarin red.
JQ1 treatment resulted in a marked decrease by 60% in
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Figure 6 | BRD4 inhibition prevents MNNG/HOS tumour bone loss. Representative microCT (a) and three-dimensional model (b) images of the tumour-
bearing tibia, taken ex vivo, from MNNG/HOS-bearing mice treated with JQ1 (50mg kg 1) or vehicle (Veh.). (c–f) MicroCTanalysis of the BV/TV (%) (c),
trabecular number (Tb.N ( per mm)) (d), trabecular thickness (Tb.Th (mm)) (f) and trabecular separation (Tb.Sp (mm)) of the tibia of tumour-bearing
mice treated JQ1 or vehicle. (g) Representative images of the ectopic bone (red) of tumour-bearing tibia, taken ex vivo, from MNNG/HOS-bearing
mice treated with JQ1 (50mg kg 1) or vehicle (Veh.). (h) MicroCT analysis of the ectopic BV (mm3). TRAP (i) and Osterix (j) were evaluated by
immunohistochemical analysis (original magniﬁcation,  200; scale bar, 200mm). Specimens were scored and estimated in % of positive cells ±s.d.
for OSTERIX, and the surface occupied by OC was determined by ImageJ in the delimited region of interest (ROI). Error bars show s.e.m. for n¼ 3
measurement from representative experiments.
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mineralization staining, indicating that BRD4 inhibition blocks
OB differentiation (Fig. 7h). This inhibition of OB differentiation
by JQ1 is completely independent of its effect on cell
proliferation/survival as revealed by cell viability assays
(Supplementary Fig. 13A). Then, we examined the expression
of RUNX2, which plays a critical role in OB differentiation, in
addition to the expression of ALP (alkaline phosphatase), a
marker of the osteoblastogenesis. JQ1 treatment leads to
signiﬁcant reduction in RUNX2 and ALP gene expression,
emphasizing the inhibitory effect of JQ1 at the transcriptional
level (Fig. 7i,j). This ﬁnding is consistent with our previous results
showing that BRD4 was detected at the RUNX2 DNA locus and
that JQ1 was able to deplete BRD4 from those sites (Fig. 4g).
Taken together, these data indicate that BRD4 inhibition with
JQ1 blocks both osteoclastogenesis and osteoblastogenesis in vitro
and in vivo. Finally and equally importantly, we found that
microCT analysis of normal bone following JQ1 treatment
showed no signiﬁcant adverse effects on bone morphometric
parameters (Supplementary Fig. 13B–F).
Discussion
The vicious cycle established between bone-associated tumours
and bone resorption is the fundamental pathophysiologic feature
of both primary bone tumours and bone metastasis1,5. While
therapeutic interventions have been developed to disrupt the
vicious cycle of bone cancer, none to our knowledge targets all
three partners of this cycle, the bone-associated tumours, OB and
OCs. For example, clinical treatment with the bisphosphonate
zoledronic acid induces apoptosis in OC and in some reports cell
death in the tumour cells31, while treatment with the anti-
RANKL monoclonal antibody denosumab inhibits OCs32. In this
study, we uncover an essential role of BET bromodomain
signalling in the vicious cycle as inhibition of BET
bromodomain signalling not only potently suppresses the
proliferation of bone-associated tumour cells but the
differentiation of both OB and OC as well. Thus, our work is
the ﬁrst to support BET bromodomain inhibition as a therapeutic
strategy to simultaneously target all three partners of the vicious
cycle, which suggest that this approach may yield better
therapeutic efﬁcacy than standard treatments for primary and
secondary bone cancer.
Since the recent discovery that BET proteins act as mediators
in the epigenetic recognition of acetylated lysines to regulate
chromatin accessibility, it has become an increasingly attractive
therapeutic target in several types of cancer19–22,26. Here we
report for the ﬁrst time data to support bromodomain inhibition
as a therapeutic strategy for bone-associated tumours. Using the
unique BET protein inhibitor JQ1, we demonstrate potent activity
against a range of human and mouse osteosarcoma cell lines as
well as in osteosarcoma preclinical models. We observe a strong
reduction in cell viability of osteosarcoma cells with BET
bromodomain inhibition irrespective of whether the oncogenic
‘driver’ was MYC or RUNX2. Furthermore, it should be noted
that the reduction of MYC gene expression does not fully account
for the anti-proliferative effect of BET inhibition, as exogenous
expression of MYC could not completely abolish the growth
inhibitory effect of JQ1. This observation led us to the ﬁnding that
BET inhibition also resulted in the downregulation of RUNX2
gene expression in osteosarcoma cells. This ﬁnding is of clinical
relevance, given the emerging role of RUNX2 as a potential
oncogene in osteosarcoma12–16. In addition, we found that
RUNX2 gene expression, as well as that of MYC and BRD4, was
higher relative to MSCs in the majority of our human
osteosarcoma patient samples suggesting an addiction or at
least a dependence to those oncogenes. This makes most
osteosarcoma patients likely to be sensitive to this BRD4-,
MYC- and RUNX2-dependent therapeutic strategy.
In our model, BRD4 actively binds to both MYC and RUNX2
gene loci, speciﬁcally at the sites of highly acetylated H3K27. In
support of this, we observe that transcriptional silencing of MYC
and RUNX2 following JQ1 treatment is associated with the release
of BRD4 proteins from their corresponding loci, indicating that
BET proteins directly regulate the expression of MYC and
RUNX2 genes. Moreover, BRD4 is released from the acetylated
histones of the MYC and RUNX2 gene loci in response to JQ1
treatment, consequently leading to their reduced gene expression.
While we observed striking anti-tumoral activity against
primary bone tumours in vivo with BET inhibition, resulting in
prolonging overall survival as well as improving tumour-
associated bone structural parameters, JQ1 had virtually no
adverse effects on normal bone architecture. Although BRD4 is
expressed in almost all tissues, no overt toxicity was detected with
high doses of JQ1. Indeed, repeated treatments with JQ1 did not
result in weight loss or other negative effects during the course of
the experiment. This highlights the importance of understanding
how the inhibition of a ubiquitous regulator like BRD4 can have
such a gene-speciﬁc effect on transcription. Interestingly, recent
studies have identiﬁed an asymmetric distribution of BRD4 at
enhancer regions across the epigenome, the so-called super-
enhancers have a high: density of transcription factors, ability to
activate transcription, levels of H3K27 acetylation and sensitivity
to perturbation by BET bromodomain inhibition28,29. These
super-enhancers are described to be associated with key cell type-
speciﬁc genes known to play prominent roles in the biology of
normal cells, and with oncogenic drivers in tumour cells.
Furthermore, JQ1 treatment of multiple myeloma tumour cells
caused the preferential loss of BRD4 at super-enhancers and
preferential loss of transcription at super-enhancer-associated
genes including the MYC oncogene. The mechanistic explanation
of this phenomenon is based on the behaviour of regular
enhancer regions, where cooperative and synergistic binding of
multiple transcription factors can occur. The more cooperatively
interacting factors there are bound on enhancers, the more
sensitive these enhancers are to small changes in transcription
factor concentration33–35. Consequently, super-enhancer regions
are extremely sensitive to reduced level of BRD4, which could
possibly explain the gene-selective effects of JQ1. It is very likely
that the new target of JQ1 identiﬁed in our study, namely,
RUNX2, ﬁt the deﬁnition of a super-enhancer. RUNX2 is not only
a key cell type gene for OB but also a potential oncogenic driver
for osteosarcoma. Moreover, we observe on ENCODE a high level
of H3K27 acetylation mark along with a very high density of
transcription factor-binding sites at the BRD4 binding sites of the
RUNX2 locus.
An unexpected ﬁnding was the effect of BET inhibition on OC
differentiation. We observed that JQ1 inhibited NFkB activity
without altering its transcription. NFkB is the key upstream
regulator of osteoclastogenesis, directly activated by RANK after
RANKL binding, and one of its primary transcriptional targets is
the transcription factor NFATC1. Under basal condition, we did
not detect binding of BRD4 to the NFATC1 promoter irrespective
of the level of H3K27 acetylation, emphasizing the possible
absence of BRD4 at some gene promoters. However, on RANKL
activation, we observed strong binding of BRD4 onto the
NFATC1 promoter at the precise NFkB consensus sites
previously reported36. Our interpretation of these results is that
BRD4 functions as a co-activator of NFkB via speciﬁc binding to
its acetylated RelA subunit. Indeed, BRD4 has been identiﬁed as a
co-activator of NFkB through its binding to the acetylated lysine-
310 of RelA37,38. In agreement with this, we also found that JQ1
abrogated BRD4 binding to NFkB consensus sites on the
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NFATC1 promoter as well as inhibited osteoclastogenesis. Similar
results were also found with MMP9, an OC functional protein.
Taken together, our results indicate that BRD4 is an essential
regulator of osteoclastogenesis and highlights the requirement
for BRD4 in regulating MYC and RUNX2 through one speciﬁc
mechanism, and NFATC1 through a completely different
mechanism.
In conclusion, pharmacological inhibition of BET bromodo-
main proteins appears to be a promising and relevant strategy for
the treatment of bone-associated tumours as it interferes with the
vicious cycle between bone tumour development and bone
remodelling. Importantly, JQ1 becomes the ﬁrst described
compound to inhibit simultaneously bone tumour growth as
well as both OB and OC differentiation. The ability of the BET
inhibitor JQ1 to target all three major components of the vicious
cycle makes it potentially less sensitive to develop treatment
resistance, an aspect that we will further investigate (Fig. 8). This
triple inhibitory effect associated with low toxicity in vivo makes
JQ1 a promising therapeutic agent for the treatment of both
primary bone tumours and bone metastasis.
Methods
Tumour cell line and patient tumour material. The human osteosarcoma cell
lines MG63 (young male osteosarcoma), SaOS2 (young female osteosarcoma),
U2OS (young female osteosarcoma from tibia origin), MNNG/HOS (young female
high-grade osteosarcoma from femur origin transformed in vitro by N-methyl-N0-
nitro-N-nitrosoguanidine treatment), KHOS (this cell line was derived from HOS
by transformation using Kirsten murine sarcoma virus (Ki-MSV), SJSA-1 (was
established in 1982 from the primary tumour of a patient diagnosed with primitive
multipotential sarcoma of the femur, there is ampliﬁcation of the gene that encodes
the p53-associated protein, MDM2, SJSA-1 cells also exhibit a 15-fold ampliﬁcation
of the gli proto-oncogene), 143B (13 years old Caucasian female, thymidine kinase
negative) G-292 (young female osteosarcoma), CAL 72 (osteosarcoma of the knee
of a 10-year-old boy) and the murine osteosarcoma cell lines POS-1 and MOS-J
were purchased from the American Type Culture Collection and maintained in
DMEM (Invitrogen-Life Technologies Inc.) supplemented with 10% fetal bovine
serum and 2mmol l 1 L-glutamine. All cell lines were cultured in a humidiﬁed 5%
CO2/air atmosphere at 37 C. All cell lines were passaged for less than 3 months.
Patient tumour biopsy specimens were collected at Nantes University Hospital
(Nantes, France). Samples were obtained following patient informed consent, and
after ethical approval by the Nantes University Hospital Ethics Committee.
Therapeutic agents. Brd4 inhibitor, JQ1, was kindly provided by James Bradner
(Dana-Farber Cancer Institute). This synthetic compound targets selectively the
acetyl-lysine-binding pocket of the BET bromodomain proteins. For in vitro
studies, JQ1 was dissolved in dimethyl sulphoxide at 10mM stock solutions and
stored at  20 C. For the in vivo studies, JQ1 was dissolved in dimethyl sulphoxide
at 50mgml 1 and then diluted in 10% hydroxypropyl beta cyclodextrin
(HP-b-CD, Sigma-Aldrich) to get the ﬁnal dose, 50mg kg 1 and stored at 4 C.
The 10% HP-b-CD is prepared in sterile water, which was ﬁltered with 0.22 m ﬁlter.
MYC expression vector and siRNA. Coding sequence for human MYC was
cloned into the expression vector pCDNA3 (Life Technologies). Transfection
was performed using Jet-PEI, according to the manufacturer’s recommendations
(Polyplus-Transfection, Illkirch, France).
For siRNA, cells were transfected with Interferin (Polyplus-Transfection) and
annealed siRNA (20 nM); (siMYC (s9129 from Ambion, Applied Biosystems,
Courtaboeuf, France) and siRUNX2 (HSS101403 from Life Tecnologies)),
according to the manufacturer’s recommendations.
Cell proliferation and apoptosis assays. Osteosarcoma cell lines were plated in
DMEM with 5% FBS and treated with JQ1 at indicated concentration, and time
and cell growth was measured using the crystal violet assay as described previously.
Detection and quantitation of dead cells were done by ﬂow cytometry (described
below) and western blotting analysis. Each assay was repeated in triplicate.
Cell cycle analysis. Osteosarcoma cell lines were incubated in the absence or the
presence of 1 mM JQ1 for 72 h, trypsinized, washed twice and incubated in PBS
containing 0.12% Triton X-100, 0.12mM EDTA and 100 mgml 1 ribonuclease A;
50 mgml 1 propidium iodide was then added to each sample for 20min at 4 C.
Cell cycle distribution was analysed by ﬂow cytometry (Cytomics FC500; Beckman
Coulter, Roissy, France) based on 2N and 4N DNA content. Each assay was done
in triplicate.
Western blotting analysis. Samples containing equal amounts of protein
(depending on the antibody, 5–50 mg) from lysates of cultured osteosarcoma
cell lines underwent electrophoresis on SDS–PAGE and were transferred to
polyvinylidene diﬂuoride membranes. The membranes were blocked in 3%
Tumour cells
BRD4 MYC
RUNX2
JQ1
RANKL
RANK
OPG
Osteoclast
Osteoblast
RUNX2BRD4
Bone matrix
P300
p50
BRD4
Ac
PTHrP,
BMP, 
VEGF…
Osteoclast
precursor
TGF-β,
IGF-1…
NFATC1
MMP9RelA
Figure 8 | BET bromodomain inhibition as a new therapeutic strategy to block the vicious cycle in bone tumours. The vicious cycle described in
primary bone tumours and bone metastases consists of release of osteolytic mediators by tumour cells and OBs, thus inducing bone degradation and
then releasing growth factors from degraded bone, enhancing tumour cell growth and further release of osteolytic mediators. In the present study,
we describe for the ﬁrst time the therapeutic interest of BET bromodomain inhibitor, JQ1, in the treatment of osteosarcoma not only by the prevention
of osteosarcoma-induced osteolysis by blocking both OC and OB differentiation, but also by the inhibition of associated tumour development, leading
to increased survival rate.
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BSA–PBS-0.1% Tween at room temperature for 1 h and blots were probed over-
night at 4 C with primary antibodies (MYC and RUNX2, 1:1,000; Cell Signaling
Technologies, Beverly, CA) or actin (1:20,000; Sigma-Aldrich) to detect proteins of
interests. After incubation, the membranes were washed three times with washing
buffer (PBS containing 0.1% Tween) for 5min. Membranes were then incubated
for 1 h with 1:10,000 diluted secondary antibodies (Santa Cruz Biotechnologies,
Santa Cruz, CA) at room temperature. Speciﬁc proteins were detected using G-Box
(Syngene, Cambridge, UK) after washing. Uncropped scans of the most important
western blots are provided as Supplementary Figs 14–16.
Quantitative reverse transcription–PCR. Total RNA was extracted from cultured
cells, human biopsies or xenografts using TRIreagent (Invitrogen-Life Technologies
Inc.). Total RNA was reversed transcribed using the ThermoScript RT–PCR
System (Life Technologies). Real-time monitoring of PCR ampliﬁcation of
complementary DNA was performed using DNA primers (primers sequences
are available in Supplementary Table 1) on CFX96 real-time PCR detector system
(Bio-Rad, Marnes la Coquette, France) with SYBR PCR Master Mix buffer
(Bio-Rad). Target gene expression was normalized to glyceraldehyde 3-phosphate
dehydrogenase levels in respective samples as an internal standard, and the
comparative cycle threshold method was used to calculated relative quantiﬁcation
of target messenger RNAs. Each assay was performed in triplicate.
qRT–PCR microRNA. A speciﬁc RT was performed for each miR from 100 ng of
total RNA, using a speciﬁc stem-loop RT primer (50 nM) and the MultiScribe
Reverse transcriptase (Applied Biosystems). The RT conditions were as follows:
30min at 16 C followed by 30 s at 20 C, 30 s at 42 C, 1 s at 50 C for 60 cycles,
and ﬁnally 5min at 85 C. Mature microRNAs’ expression levels were measured by
real-time qRT–PCR using the SYBR PCR Master Mix buffer (Bio-Rad) and an
CFX96 real-time PCR detector system (Bio-Rad). The expression of each gene was
normalized to the small nuclear U6B RNA or 5S ribosomal RNA as a reference.
All experiments were performed in triplicate. Primers sequences are available in
Supplementary Table 2.
Quantitative ChIP assay. A ChIP assay was performed by the Magnify ChIP
system (Invitrogen-Life Technologies Inc.) using 5 mg of BRD4 antibody (Bethyl
Lab) or control rabbit IgG (R&D Systems). Real-time PCR (Bio-Rad) was
performed on fragmented DNA using speciﬁc primers for the MYC, RUNX2,
NFATC1, MMP9 and IL7R loci. Primers were designed to amplify sites within each
gene locus based on the H3K27 acetylation level, and a negative control region was
designed outside the promoter region (primers sequences are available in
Supplementary Table 3). The levels of enrichment of the H3K27Ac histone mark
across the genome has been determined by a ChIP-seq assay on seven cell lines
from ENCODE web resourses.
Luciferase assay. The cell line HEK293 overexpressing RANK was obtained by
transducing cells with lentivirus containing the coding sequence of RANK and
were then selected with antibiotic selection.
HEK293-RANK cells were seeded in 24-well plates and were transfected with
the indicated ﬁreﬂy luciferase constructs (pNF-kB-Luc reporter, BD Biosciences,
Clonetech) together with an SV40-renilla control vector. Lysates were prepared at
40 h, and luciferase activity was measured using the Dual Luciferase Reporter Assay
system (Promega) and a luminometer (MicroLumat Plus; EG&G Berthold).
OC differentiation. OCs were generated from human CD14þ monocytes.
Puriﬁed CD14þ cells were cultured in a-MEM with 10% FCS and 25 ng0060ml 1
human macrophage colony stimulating factor (R&D Systems). After 4 days of
culture, 100 ngml 1 hRANKL and 125 nM JQ1 were added. Multinucleated cells
formed with three nuclei and more were counted after TRAP staining (Sigma,
France)39.
OB differentiation. Before passage 5, MSCs were seeded at 104 cells per cm2 in
96-well plates in DMEM supplemented with vitamin D3 (10 8M; Hoffmann-La
Roche, Basel, Switzerland), dexamethasone (10 8M; Sigma) and with or without
JQ1 as indicated (this represented day 0 for MSC osteogenic differentiation).
Three days later, freshly prepared ascorbic acid (50 mgml 1; Sigma) and
b-glycerophosphate (10mM; Sigma) was added to allow mineralization, this
medium being changed every 2–3 days. Alizarin red-S staining was used to detect
the mineralized nodules formed in vitro as described previously40. In brief, between
day 19 and 21, cells were ﬁxed in ice-cold 70% ethanol for 1 h and incubated with
alizarin red-S (40mM, pH 7.4; Sigma) for 10min at room temperature. After
extensive washing, images were captured using a stereo microscope (Stemi 2000-C;
Zeiss, Oberkochen, Germany, http://www.zeiss.com), and mineralized surfaces
were quantiﬁed using the Qwin software (Leica, Nussloch, Germany, http://
www.leica-microsystems.com).
Animal treatment. All procedures involving mice (their housing in the Experi-
mental Therapeutic Unit at the Faculty of Medicine of Nantes (France) and care,
the method by which they were anaesthetized and killed, and all experimental
protocols) were conducted in accordance with the institutional guidelines of the
French Ethical Committee (CEEA.PdL.06). Mice were anaesthetized by inhalation
of a combination of isoﬂurane/air (1.5%, 1 lmin 1) and buprenorphine
(0.05mg kg 1; Temge´sic, Schering-Plough). Tumour volume was measured three
times weekly and tumour volume was calculated by using the formula: length
width depth 0.5432. Data points were expressed as average tumour volume
±s.e.m.
HOS osteolytic xenograft model was induced by an intramuscular injection of
2 106 human HOS cells next to the tibia of 5-week-old female athymic nude mice
(Harlan Sprague–Dawley Inc.), leading to a rapidly growing tumour in soft tissue
with secondary contiguous bone invasion. Once palpable tumours, mice were
randomly assigned to vehicle or JQ1. When tumours reached 100mm3, JQ1
(50mg kg 1; formulation in 10% HP-b-CD in sterile water) is IP injected twice
a day, every day. Each experimental group consisted of eight mice.
To establish syngenic POS-1 tumour model, 5-week-old male C3H/He mice
were anaesthetized before subcutaneous inoculation of POS-1 cell suspension
(containing 2 106 cells) in the hind footpad of the mice. Under these conditions,
mice develop a primary tumour at the site of injection in 3 weeks that can be
transplanted to mice of the same strain as a small fragment (2 2 2mm3) in
close contact with the tibia. For this purpose, the periostum of the diaphysis was
opened and resected along a length of 5mm, and the underlying bone was intact.
The osteosarcoma fragment was placed contiguous to the exposed bone surface
without the periostum, and the cutaneous and muscular wounds were sutured.
Tumours appeared at the graft siteB8 days later associated with the development
of pulmonary metastases in a 3-week period. The tumours that develop in contact
to the femora lead to osteolytic lesions that reproduce the osteolytic form of human
osteosarcoma41. When tumours reached 100mm3, mice were randomly selected
for treatment with vehicule or JQ1 (50mg kg 1). JQ1 was injected I.P twice a day,
every day. Each experimental group consisted of six mice.
When tumour volume reached Z10% of body weight, mice were killed and
tumours harvested for evaluation of protein expression by western blotting analyses
and immunohistochemistry.
MicroCT analysis. MicroCT analysis has been previously described42. In brief,
tibias were scanned using high-resolution microcomputed tomography (Skyscan
1076, Kontich, Belgium) at 50 kV and 200 mA using a 0.5-mm aluminium ﬁlter and
a detection pixel size of 9 mm. Images were captured every 0.6 through 180
rotation, and analysed using Skyscan software. Trabecular structures positioned
0.2mm below the growth plate were quantiﬁed over a length of 1mm.
BV/TV, trabecular thickness, trabecular separation and Tb.N. were determined.
The BV of ectopic bone was quantiﬁed over the total length of tibia bearing
tumour.
Bone histomorphometric analysis and immunohistochemistry. Tibias were
decalciﬁed with 4.13% EDTA and 0.2% paraformaldehyde in PBS for 96 h using the
KOS microwave histostation (Milestone, Kalamazoo, MI, http://www.milestone-
med.com) before embedding in parafﬁn. Sections (3 mm thick, Leica Microsystems)
were analysed by TRAP staining as described previously43,44. Immunostaining for
Osterix was performed as described43 with a rabbit anti-osterix antibody (1/25;
Abcam, Cambridge, MA, http://www.abcam.com). Quantiﬁcation of relative OC
surface (TRAPþ cells) and OB number (osterixþ cells) in the metaphyseal
spongiosa was evaluated by Qwin (Leica) and ImageJ (NIH, Bethesda, MD)
softwares. Immunostaining for Ki67 was conducted using a primary antibody
mouse anti-human Ki67 (1:100; Dako) on tumour section. All analyses were
assessed by light microscopy using a DMRXA microscope (Leica). All comparisons
of staining intensities were made at  200 magniﬁcations.
Statistical analysis. For each experimental data point, the s.e.m. from replicate
experiments was calculated as noted in the legends and is shown as error bars.
All error bars show s.e.m. for at least triplicate measurement from representative
experiments. The mean±s.e.m. was calculated for all groups and compared by
two-tailed paired Student’s t-test or by analysis of variance, with the Bonferroni
multiple comparisons test for post hoc analysis. Unless otherwise stated, multiple
comparisons were performed by analysis of variance. Po0.05 was used as the
criteria for statistical signiﬁcance.
For Figs 1b and 4b, the Pearson product-moment correlation coefﬁcient (R2)
was calculated and a two-tailed P-value was generated from a probability table.
Prism 3.0 software was used for all statistical analysis.
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